$12.52
0.52% today
Nasdaq, Nov 06, 10:00 pm CET
ISIN
US67080M1036
Symbol
NRIX

Nurix Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Nurix Therapeutics Inc Classifications & Recommendation:

Buy
88%
Hold
12%

Nurix Therapeutics Inc Price Target

Target Price $28.56
Price $12.46
Potential
Number of Estimates 21
21 Analysts have issued a price target Nurix Therapeutics Inc 2026 . The average Nurix Therapeutics Inc target price is $28.56. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 25 analysts: 22 Analysts recommend Nurix Therapeutics Inc to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Nurix Therapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the Nurix Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Nov '24 2025
Estimates
Revenue Million $ 54.55 97.21
29.15% 78.20%
EBITDA Margin -373.44% -244.82%
94.88% 34.44%
Net Margin -354.85% -258.48%
89.79% 27.16%

20 Analysts have issued a sales forecast Nurix Therapeutics Inc 2025 . The average Nurix Therapeutics Inc sales estimate is

$97.2m
Unlock
. This is
16.15% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$119m 41.73%
Unlock
, the lowest is
$74.5m 11.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $54.6m 29.15%
2025
$97.2m 78.20%
Unlock
2026
$62.7m 35.48%
Unlock
2027
$86.5m 37.99%
Unlock
2028
$171m 97.35%
Unlock
2029
$342m 100.50%
Unlock
2030
$545m 59.24%
Unlock
2031
$762m 39.67%
Unlock
2032
$1.1b 45.36%
Unlock

5 Analysts have issued an Nurix Therapeutics Inc EBITDA forecast 2025. The average Nurix Therapeutics Inc EBITDA estimate is

$-238m
Unlock
. This is
9.66% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-188m 28.69%
Unlock
, the lowest is
$-282m 7.05%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-204m 38.08%
2025
$-238m 16.82%
Unlock
2026
$-305m 27.98%
Unlock
2027
$-306m 0.53%
Unlock

EBITDA Margin

2024 -373.44% 94.88%
2025
-244.82% 34.44%
Unlock
2026
-485.64% 98.37%
Unlock
2027
-353.80% 27.15%
Unlock

21 Nurix Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Nurix Therapeutics Inc net profit estimate is

$-251m
Unlock
. This is
2.64% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-224m 8.34%
Unlock
, the lowest is
$-255m 4.33%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-194m 34.47%
2025
$-251m 29.80%
Unlock
2026
$-295m 17.48%
Unlock
2027
$-275m 6.82%
Unlock
2028
$-229m 16.84%
Unlock
2029
$-135m 41.17%
Unlock
2030
$7.7m 105.74%
Unlock
2031
$178m 2,198.45%
Unlock
2032
$364m 104.94%
Unlock

Net Margin

2024 -354.85% 89.79%
2025
-258.48% 27.16%
Unlock
2026
-470.69% 82.10%
Unlock
2027
-317.85% 32.47%
Unlock
2028
-133.94% 57.86%
Unlock
2029
-39.30% 70.66%
Unlock
2030
1.42% 103.61%
Unlock
2031
23.33% 1,542.96%
Unlock
2032
32.89% 40.98%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Nov '24 2025
Estimates
Earnings Per Share $ -2.88 -3.27
8.68% 13.54%
P/E negative
EV/Sales 8.58

21 Analysts have issued a Nurix Therapeutics Inc forecast for earnings per share. The average Nurix Therapeutics Inc EPS is

$-3.27
Unlock
. This is
12.76% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-2.92 0.69%
Unlock
, the lowest is
$-3.32 14.48%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-2.88 8.68%
2025
$-3.27 13.54%
Unlock
2026
$-3.84 17.43%
Unlock
2027
$-3.58 6.77%
Unlock
2028
$-2.98 16.76%
Unlock
2029
$-1.75 41.28%
Unlock
2030
$0.10 105.71%
Unlock
2031
$2.31 2,210.00%
Unlock
2032
$4.74 105.19%
Unlock

P/E ratio

Current -4.29 57.35%
2025
-3.81 11.29%
Unlock
2026
-3.24 14.96%
Unlock
2027
-3.48 7.41%
Unlock
2028
-4.19 20.40%
Unlock
2029
-7.11 69.69%
Unlock
2030
123.84 1,841.77%
Unlock
2031
5.39 95.65%
Unlock
2032
2.63 51.21%
Unlock

Based on analysts' sales estimates for 2025, the Nurix Therapeutics Inc stock is valued at an EV/Sales of

and an P/S ratio of
12.99
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 9.96 56.28%
2025
8.58 13.89%
Unlock
2026
13.29 55.00%
Unlock
2027
9.63 27.53%
Unlock
2028
4.88 49.33%
Unlock
2029
2.43 50.12%
Unlock
2030
1.53 37.20%
Unlock
2031
1.09 28.40%
Unlock
2032
0.75 31.21%
Unlock

P/S ratio

Current 15.09 50.90%
2025
12.99 13.91%
Unlock
2026
20.13 55.00%
Unlock
2027
14.59 27.53%
Unlock
2028
7.39 49.33%
Unlock
2029
3.69 50.12%
Unlock
2030
2.32 37.20%
Unlock
2031
1.66 28.40%
Unlock
2032
1.14 31.20%
Unlock

Current Nurix Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Needham
Locked
Locked
Locked Nov 04 2025
BTIG
Locked
Locked
Locked Nov 04 2025
HC Wainwright & Co.
Locked
Locked
Locked Oct 27 2025
BTIG
Locked
Locked
Locked Oct 23 2025
Wells Fargo
Locked
Locked
Locked Oct 23 2025
Needham
Locked
Locked
Locked Oct 22 2025
Mizuho
Locked
Locked
Locked Oct 21 2025
Analyst Rating Date
Locked
Needham:
Locked
Locked
Nov 04 2025
Locked
BTIG:
Locked
Locked
Nov 04 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Oct 27 2025
Locked
BTIG:
Locked
Locked
Oct 23 2025
Locked
Wells Fargo:
Locked
Locked
Oct 23 2025
Locked
Needham:
Locked
Locked
Oct 22 2025
Locked
Mizuho:
Locked
Locked
Oct 21 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today